Fingerprint
Dive into the research topics of 'Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
Samir D. Undevia, Nicholas J. Vogelzang, Ann M. Mauer, Linda Janisch, Sridhar Mani, Mark J. Ratain
Research output: Contribution to journal › Article › peer-review
39
Scopus
citations